

# Scott D Nelson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6432043/publications.pdf>

Version: 2024-02-01

81  
papers

2,089  
citations

249298

26  
h-index

299063

42  
g-index

82  
all docs

82  
docs citations

82  
times ranked

1771  
citing authors

#	ARTICLE	IF	CITATIONS
1	Electronic Health Recordâ€™Integrated Tumor Board Application to Save Preparation Time and Reduce Errors. JCO Clinical Cancer Informatics, 2022, 6, e2100142.	1.0	1
2	Personalized chordoma organoids for drug discovery studies. Science Advances, 2022, 8, eabl3674.	4.7	29
3	Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma. Cancer Medicine, 2022, 11, 2906-2912.	1.3	4
4	Limitations of dual-energy CT in the detection of monosodium urate deposition in dense liquid tophi and calcified tophi. Skeletal Radiology, 2021, 50, 1667-1675.	1.2	9
5	Recurrence and disease-specific survival after 10-year disease-free interval in patients with primary retroperitoneal liposarcoma: Implications for long-term surveillance.. Journal of Clinical Oncology, 2021, 39, 11546-11546.	0.8	0
6	Prediction of soft tissue sarcoma response to radiotherapy using longitudinal diffusion MRI and a deep neural network with generative adversarial networkâ€™based data augmentation. Medical Physics, 2021, 48, 3262-3372.	1.6	11
7	Tâ€™LAK cellâ€™originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma. Molecular Oncology, 2021, 15, 3721-3737.	2.1	5
8	Wide en bloc resection of an extraskeletal myxoid chondrosarcoma about the knee with single-stage knee extensor mechanism reconstruction: A case report. Knee, 2021, 31, 77-85.	0.8	0
9	Patient-derived orthotopic xenograft models of sarcoma. Cancer Letters, 2020, 469, 332-339.	3.2	17
10	Establishment and Characterization of a Recurrent Osteosarcoma Cell Line: OSA 1777. Journal of Orthopaedic Research, 2020, 38, 902-910.	1.2	10
11	Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications. Cancer Treatment Reviews, 2020, 82, 101934.	3.4	45
12	Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value. European Spine Journal, 2020, 29, 3214-3228.	1.0	7
13	Tâ€™LAK cellâ€™originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma. Cell Proliferation, 2020, 53, e12901.	2.4	11
14	Chemotherapy and Survival in Patients with Primary High-Grade Extremity and Trunk Soft Tissue Sarcoma. Cancers, 2020, 12, 2389.	1.7	9
15	Evading the host response: Staphylococcus â€™hidingâ€™ in cortical bone canalicular system causes increased bacterial burden. Bone Research, 2020, 8, 43.	5.4	19
16	A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. Cancer Genomics and Proteomics, 2020, 17, 217-223.	1.0	7
17	Recombinant Methioninase Combined With Tumor-targeting <i>Salmonella typhimurium</i> A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated Liposarcoma. Anticancer Research, 2020, 40, 2515-2523.	0.5	4
18	Treatment effect prediction for sarcoma patients treated with preoperative radiotherapy using radiomics features from longitudinal diffusion-weighted MRIs. Physics in Medicine and Biology, 2020, 65, 175006.	1.6	38

#	ARTICLE	IF	CITATIONS
19	A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 1829-1836.	3.2	63
20	Exquisite Tumor Targeting by Salmonella A1-R in Combination with Caffeine and Valproic Acid Regresses an Adult Pleomorphic Rhabdomyosarcoma Patient-Derived Orthotopic Xenograft Mouse Model. <i>Translational Oncology</i> , 2020, 13, 393-400.	1.7	7
21	Exogenous Ochronosis (EO): Skin lightening cream causing rare caviar-like lesion with banana-like pigments; review of literature and histological comparison with endogenous counterpart. <i>Autopsy and Case Reports</i> , 2020, 10, e2020197.	0.2	5
22	Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Journal of Drug Targeting</i> , 2019, 27, 211-216.	2.1	11
23	Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Anticancer Research</i> , 2019, 39, 4775-4779.	0.5	16
24	Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model. <i>Biochemical and Biophysical Research Communications</i> , 2019, 509, 1041-1046.	1.0	12
25	The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109093.	2.5	4
26	Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2019, 58, 107-111.	1.0	3
27	Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2019, 58, 17-23.	1.0	10
28	Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 809-815.	1.1	16
29	Advances in immune checkpoint inhibitors for bone sarcoma therapy. <i>Journal of Bone Oncology</i> , 2019, 15, 100221.	1.0	122
30	A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma. <i>Pharmacological Research</i> , 2019, 142, 169-175.	3.1	14
31	Oncologic Accuracy of Image-guided Percutaneous Core-Needle Biopsy of Peripheral Nerve Sheath Tumors at a High-volume Sarcoma Center. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 739-743.	0.6	12
32	The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Biomedicine and Pharmacotherapy</i> , 2019, 111, 835-840.	2.5	10
33	Detection of Metastasis in a Patient-derived Orthotopic Xenograft (PDOX) Model of Undifferentiated Pleomorphic Sarcoma with Red Fluorescent Protein. <i>Anticancer Research</i> , 2019, 39, 81-85.	0.5	19
34	Epithelioid Osteoblastoma of the Temporal Bone: A Case Report. <i>World Neurosurgery</i> , 2019, 123, 378-382.	0.7	7
35	Primary pulmonary undifferentiated pleomorphic sarcoma (PPUPS). <i>Autopsy and Case Reports</i> , 2019, 9, e2019110.	0.2	7
36	Glomus tumor of uncertain malignant potential of the brachial plexus: A case report. <i>World Journal of Clinical Cases</i> , 2019, 7, 2815-2822.	0.3	2

#	ARTICLE	IF	CITATIONS
37	Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Cell Cycle</i> , 2018, 17, 722-727.	1.3	9
38	Tumor-targeting <i>Salmonella typhimurium</i> A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. <i>Biochemical and Biophysical Research Communications</i> , 2018, 497, 1055-1061.	1.0	28
39	Tumor-targeting <i>Salmonella typhimurium</i> A1-R combined with recombinant methioninase and cisplatin eradicates an osteosarcoma cisplatin-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic. <i>Cell Cycle</i> , 2018, 17, 801-809.	1.3	57
40	Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone. <i>Journal of Infectious Diseases</i> , 2018, 217, 1770-1781.	1.9	23
41	Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. <i>Cell Cycle</i> , 2018, 17, 627-633.	1.3	13
42	Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. <i>Cancer Letters</i> , 2018, 417, 168-173.	3.2	56
43	Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention. <i>Cell Cycle</i> , 2018, 17, 356-361.	1.3	40
44	Growth of doxorubicin-resistant undifferentiated spindle cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 3537-3544.	1.2	30
45	Combining Tumor-Selective Bacterial Therapy with <i>Salmonella typhimurium</i> A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model. <i>Chemotherapy</i> , 2018, 63, 278-283.	0.8	25
46	Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 912-917.	1.0	29
47	A combination of irinotecan/cisplatin and irinotecan/temozolomide or tumor-targeting <i>Salmonella typhimurium</i> A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2018, 505, 733-739.	1.0	18
48	Tumor-targeting <i>Salmonella typhimurium</i> A1-R overcomes partial carboplatin-resistance of a cancer of unknown primary (CUP). <i>Tissue and Cell</i> , 2018, 54, 144-149.	1.0	8
49	Combination therapy of tumor-targeting <i>Salmonella typhimurium</i> A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 3086-3092.	1.0	27
50	Tumor-targeting <i>Salmonella typhimurium</i> A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 7827-7833.	1.2	6
51	Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting <i>S. typhimurium</i> A1-R is superior to first-line chemotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 12.	7.1	5
52	Temozolomide regresses a doxorubicin-resistant undifferentiated spindle cell sarcoma patient-derived orthotopic xenograft (PDOX): precision oncology nude mouse model matching the patient with effective therapy. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 6598-6603.	1.2	14
53	Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2018, 53, 30-36.	1.0	18
54	Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>BMC Cancer</i> , 2018, 18, 840.	1.1	14

#	ARTICLE	IF	CITATIONS
55	Tumor-targeting <i>Salmonella typhimurium</i> A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations. <i>Heliyon</i> , 2018, 4, e00643.	1.4	11
56	Temozolomide combined with irinotecan regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. <i>Oncotarget</i> , 2018, 9, 7774-7781.	0.8	22
57	Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. <i>Oncotarget</i> , 2018, 9, 915-923.	0.8	42
58	Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Oncotarget</i> , 2018, 9, 11119-11125.	0.8	35
59	Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2018, 9, 19263-19272.	0.8	22
60	Tumor-Targeting <i>Salmonella typhimurium</i> A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2314-2319.	1.2	53
61	High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2739-2743.	1.2	34
62	Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. <i>Cell Cycle</i> , 2017, 16, 1063-1069.	1.3	30
63	Angiosarcoma of the tongue: A case series and literature review. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2017, 38, 475-478.	0.6	8
64	<i>Salmonella typhimurium</i> A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. <i>Cell Cycle</i> , 2017, 16, 1288-1294.	1.3	37
65	The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago. <i>Cell Cycle</i> , 2017, 16, 1046-1052.	1.3	38
66	Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model. <i>Cell Cycle</i> , 2017, 16, 91-94.	1.3	41
67	Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2017, 8, 35630-35638.	0.8	77
68	Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2017, 8, 75874-75880.	0.8	33
69	Toxicology and efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R compared to VNP 20009 in a syngeneic mouse tumor model in immunocompetent mice. <i>Oncotarget</i> , 2017, 8, 54616-54628.	0.8	16
70	A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatin and doxorubicin in a patient-derived orthotopic xenograft (PDOX). <i>Oncotarget</i> , 2017, 8, 63353-63359.	0.8	24
71	A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatin-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. <i>Oncotarget</i> , 2017, 8, 62111-62119.	0.8	48
72	Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2017, 8, 85516-85525.	0.8	67

#	ARTICLE	IF	CITATIONS
73	The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and <i>CDKN2A</i> deletion: Direction for third-line patient therapy. <i>Oncotarget</i> , 2017, 8, 103129-103136.	0.8	38
74	Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines. <i>Anticancer Research</i> , 2017, 37, 4081-4084.	0.5	5
75	Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2016, 7, 71737-71743.	0.8	72
76	Current management of aneurysmal bone cysts. <i>Current Reviews in Musculoskeletal Medicine</i> , 2016, 9, 435-444.	1.3	149
77	Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. <i>Oncotarget</i> , 2016, 7, 64300-64308.	0.8	44
78	Tumor-targeting <i>Salmonella typhimurium</i> A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. <i>Oncotarget</i> , 2016, 7, 85929-85936.	0.8	77
79	Ewing Sarcoma in a Patient With Cowden Syndrome. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1310-1314.	2.3	5
80	Risk stratification of patients undergoing pulmonary metastasectomy for soft tissue and bone sarcomas. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, 85-92.	0.4	52
81	Disseminated Coccidioidomycosis Detected by Percutaneous Liver Biopsy in a Liver Transplant Recipient. <i>American Journal of Clinical Pathology</i> , 1990, 93, 141-144.	0.4	21